Marshall Wace, LLP Guardant Health, Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $2.05 Million - $3.23 Million	119,878 New	119,878 $2.47 Million
Q2 2023 Aug 14, 2023	BUY	$20.94 - $38.01 $6.97 Million - $12.6 Million	332,733 Added 1615.21%	353,333 $12.6 Million
Q1 2023 May 15, 2023	BUY	$22.92 - $33.76 $288,929 - $425,578	12,606 Added 157.69%	20,600 $482,000
Q4 2022 Feb 14, 2023	BUY	$25.44 - $59.78 $203,367 - $477,881	7,994 New	7,994 $217,000
Q1 2022 May 16, 2022	SELL	$48.25 - $100.49 $190,780 - $397,337	-3,954 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$88.71 - $120.43 $29.5 Million - $40 Million	-332,250 Reduced 98.82%	3,954 $396,000
Q2 2021 Aug 13, 2021	BUY	$109.77 - $165.68 $31.7 Million - $47.9 Million	288,913 Added 610.93%	336,204 $41.8 Million
Q1 2021 May 17, 2021	SELL	$127.04 - $179.1 $114 Million - $161 Million	-899,591 Reduced 95.01%	47,291 $7.22 Million
Q4 2020 Feb 16, 2021	BUY	$99.96 - $135.93 $1.53 Million - $2.08 Million	15,300 Added 1.64%	946,882 $122 Million
Q3 2020 Nov 16, 2020	SELL	$80.32 - $111.8 $47.1 Million - $65.6 Million	-586,500 Reduced 38.63%	931,582 $104 Million
Q2 2020 Aug 13, 2020	BUY	$60.49 - $97.5 $50.4 Million - $81.2 Million	833,174 Added 121.65%	1,518,082 $123 Million
Q1 2020 May 15, 2020	BUY	$59.04 - $88.81 $40.4 Million - $60.8 Million	684,908 New	684,908 $47.7 Million

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.23B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.